Alcanza Clinical Research Expands Network Through Strategic Acquisition of Tampa Bay Medical Research
核心洞察
Alcanza Clinical Research (搜索) has acquired Tampa Bay Medical Research (搜索) (TBMR), an independent clinical research center with nearly four decades of experience and over 600 completed trials.
TBMR operates facilities totaling over 5,000 square feet in Clearwater and Largo, Florida, conducting Phase II-IV trials across therapeutic areas including MASH/MASLD (搜索), metabolic disease (搜索), and endocrinology.
The acquisition strengthens Alcanza's national network of 25 dedicated research units, expanding access to clinical trials for underrepresented communities while preserving TBMR's local expertise.
Alcanza Clinical Research (搜索) has completed the strategic acquisition of Tampa Bay Medical Research (搜索) (TBMR), a well-established independent clinical research center that has been advancing medical science in Florida for nearly four decades. The acquisition, facilitated by Westcove Partners (搜索) as exclusive financial advisor to TBMR, represents a significant expansion of Alcanza's national clinical research network.
Established Research Platform with Proven Track Record
Founded in 1984, Tampa Bay Medical Research (搜索) has completed more than 600 clinical trials across a broad spectrum of therapeutic areas for over 70 pharmaceutical and medical device sponsors. The organization operates facilities totaling over 5,000 square feet in Clearwater and Largo, Florida, conducting Phase II-IV trials in areas including MASH/MASLD (搜索), metabolic disease (搜索), endocrinology, and vaccines.
TBMR has built a reputation for excellence in clinical operations, supported by a multidisciplinary team of Principal Investigators, certified clinical research coordinators, and support staff. The center's community-first approach has consistently delivered reliable enrollment and high-quality trial execution for sponsors seeking clinical data in a patient-centric research environment.
Leadership Continuity and Expertise
Dr. Sureka Bollepalli, CEO and Medical Director of TBMR, will continue leading the Tampa Bay operations. A board-certified endocrinologist with over 20 years of experience conducting NIH and industry-sponsored trials, Dr. Bollepalli has established herself as a long-standing leader within the metabolic research community, overseeing studies from initiation through execution and close-out.
"We are excited to begin this next chapter with Alcanza Clinical Research (搜索). This partnership strengthens our ability to support patients, deepen community engagement, and expand access to high-quality clinical research—allowing us to advance care and improve lives together," said Dr. Bollepalli.
Strategic Network Expansion
The acquisition aligns with Alcanza's mission to expand its national footprint while preserving local expertise and personalized care. Carlos Orantes, CEO of Alcanza Clinical Research (搜索), emphasized the strategic importance of the partnership: "Partnering with high quality clinical research businesses and operators remains a top priority for us. We are very excited to welcome Dr. Bollepalli and her TBMR team to the Alcanza family."
Alcanza operates an integrated network of 25 dedicated research units and additional integrated specialty clinic sites strategically located throughout the Southeast, Northeast, Southwest, Midwest, and Puerto Rico. The network focuses on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, with particular emphasis on underrepresented communities.
Transaction Advisory and Market Impact
Westcove Partners (搜索), a healthcare-focused investment bank, served as exclusive financial advisor to TBMR in the transaction. The Westcove deal team included Justin Hand, Managing Director; Bill Bolding, Vice President; Geno Catalano, Associate; and Andrew Hartono, Analyst. Transaction terms were not disclosed.
Bill Bolding of Westcove commented on the strategic fit: "Dr. Bollepalli has built a high-quality clinical research platform with a strong track record of execution. Alcanza is a natural partner for TBMR, bringing scale and infrastructure that support continued growth while preserving the strengths of the existing site."
The combined organization is positioned to accelerate clinical research and broaden access to innovative treatment opportunities by integrating TBMR's operational excellence and community presence with Alcanza's scalable infrastructure and strategic partnerships. This acquisition represents a significant milestone in expanding clinical trial access while maintaining the quality standards that both organizations' participants and sponsors have come to expect.